Physician profile
Cheryl Silverbrook
NPI 1992149876
$3,408.38
in general payments reported to CMS, 2019-2025
31 companies · $879 in 2025
The $879 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $278 · 2021: $467 · 2022: $696 · 2023: $565 · 2024: $236 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,594 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,594.29 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $597.07 | 2019-2025 | Liletta, Orilissa, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $342.24 | 2022-2025 | |
| Hologic Sales and Service, LLC | $230.32 | 2019-2025 | Myosure Tissue Removal Device, Omni Hysteroscope, Novasure |
| Astellas Pharma US INC | $217.71 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $200.30 | 2021-2023 | |
| Myovant Sciences INC. | $162.08 | 2021-2022 | |
| Therapeuticsmd, INC. | $155.48 | 2019-2022 | |
| Sage Therapeutics, LLC | $135.29 | 2021-2025 | Zurzuvae |
| Mylan Pharmaceuticals INC. | $127.56 | 2021-2022 | |
| Organon LLC | $126.66 | 2021-2025 | Nexplanon |
| Aspira Women'S Health INC | $106.92 | 2022 | |
| Evofem Biosciences, INC. | $104.48 | 2021-2023 | Phexxi |
| Coopersurgical, INC. | $103.93 | 2019-2024 | Summit Doppler, Paragard T 380a |
| Exeltis, USA INC. | $88.50 | 2022-2025 | Slynd |
| Merck Sharp & Dohme LLC | $80.16 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $75.72 | 2023 | Myrisk |
| Optumhealth Care Solutions, LLC | $75.14 | 2024-2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Sumitomo Pharma America, INC. | $75.10 | 2023-2024 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $73.62 | 2020-2025 | |
| Lupin INC. | $45.88 | 2020 | |
| Millicent US INC | $45.49 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Mission Pharmacal Company | $42.35 | 2019 | |
| Avion Pharmaceuticals | $41.14 | 2021-2022 | |
| Shield Therapeutics INC | $27.56 | 2025 | |
| Dysis Medical, INC. | $27.18 | 2021 | |
| Allergan, INC. | $21.85 | 2019 | |
| Supernus Pharmaceuticals, INC. | $21.05 | 2025 | Qelbree |
| Davol INC. | $19.96 | 2020 | |
| Scynexis, INC. | $13.36 | 2022 | |
| Amag Pharmaceuticals, INC. | $12.81 | 2019 | |
| Meditrina | $11.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Silverbrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.